Objectives: To assess the impact of low flow with and without preserved left ventricular ejection fraction (LVEF) on outcomes after transcatheter aortic valve replacement (TAVR).
| I N TR ODU C TI ON
Transcatheter aortic valve replacement (TAVR) is an effective treatment for patients with severe aortic stenosis (AS) at intermediate, high, or prohibitive risk of major complications with surgical aortic valve replacement (SAVR) [1] [2] [3] . As the use of TAVR expands, it is helpful for clinicians to understand which patients are likely to derive the most benefit and which are likely to be at highest risk for adverse outcomes.
Traditional severe AS is defined by major societal guidelines as an aortic valve area (AVA) < 1.0 cm 2 , a peak transaortic velocity > 4.0 m/s, and a mean transaortic gradient > 40 mm Hg [4, 5] . However, patients with severe AS frequently have discordant echocardiographic findings, some of which have been shown to carry prognostic significance.
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Reduced left ventricular ejection fraction (LVEF) has previously been associated with worse outcomes after SAVR [6, 7] . However, recent studies have shown that patients with reduced LVEF have similar outcomes to those with preserved LVEF after TAVR [6, 8, 9] . Low aortic valve gradient (AVG) has been associated with poor outcomes after both TAVR and SAVR when compared to patients with normal AVG [7, 9, 10] . When low LVEF and AVG have been studied together in a modern TAVR population, low AVG was independently associated with higher rates of mortality and heart failure (HF) readmission after TAVR, whereas low LVEF was not an independent predictor of poor outcomes [9] .
Reduced transaortic flow, as measured by the stroke volume index, is another hemodynamic parameter associated with poor outcomes in patients with severe AS, and prior studies have suggested that patients with preserved LVEF and both low flow and low AVG (Stage D3 AS per the ACC/AHA classification system) experience the worst outcomes when compared to other flow and gradient profiles [7, [11] [12] [13] [14] [15] .
This 'paradoxical' low flow, low AVG state is associated with a small ventricular cavity size, poor diastolic filling, and concentric hypertrophy, and may be indicative of alternative processes that are not entirely modified by AVR [7, 12] . With respect to TAVR, a few studies have similarly found that low flow is associated with increased mortality and HF readmission after TAVR, and may be a stronger independent predictor than either low AVG or LVEF, which may be less prognostic when adjusting for flow [11, 14] .
As TAVR use has expanded to a greater range of patients, there are limited data on how low flow compares with AVG and LVEF in predicting poor outcomes in a modern TAVR population, and it is unclear how the outcomes of patients with low flow and preserved LVEF compare with those of patients with low flow and reduced LVEF. To examine these questions, we collected hemodynamic parameters and analyzed outcomes from a TAVR population at Brigham and Women's Hospital. 
| Statistical Analysis
Normally distributed continuous variables are expressed as means and standard deviation and were compared using Student's t-tests with Levene's test for homogeneity of variance. Non-normally distributed variables are expressed as median and inter-quartile range (IQR) and were compared using Mann-Whitney U tests. Categorical variables are presented as frequencies and percentages and compared using v2 or Fisher's exact tests. Longitudinal time-to-event outcomes were estimated by Kaplan-Meier analyses. Adjusted time-to-event analyses were performed using forward stepwise COX proportional hazards models with a 0.1 significance level to enter and 0.05 significance level to stay. Covariates included in the models included flow, AVG, LVEF, age, sex, diabetes, hypertension, atrial fibrillation, peripheral artery disease, prior stroke, current dialysis, mean creatinine, prior coronary stent, prior coronary artery bypass graft surgery, prior pacemaker, prior valve procedure, chronic lung disease, New York Heart Association functional class, current coronary disease, STS score, access site, transcatheter valve type, and valve-in-valve TAVR. All analyses were conducted using SAS Software version 9.4 (SAS Institute, Cary, NC) and P 0.05 was the criterion for statistical significance. 16.4%; P < 0.001) and low mean AVG (71.9 vs. 26.2%; P < 0.001).
With respect to in-hospital outcomes, patients with low flow had significantly higher rates of mortality (12.5% vs. 2.1%, P < 0.001) and need for blood transfusion (32.3% vs. 18.4%, P 5 0.0029), in addition to longer durations of hospital admission (7.1 vs. 4.9 days; P 5 0.0041) and time spent in an intensive care unit (63.5 vs. 35.7 hours; P 5 0.024) ( Table 2 ). At 30 days, patients with low flow had significantly higher rates of mortality (15.6 vs. 2.5%; P < 0.001) and readmission for HF (8.6 vs. 2.1%; P 5 0.011) ( Table 3) . In the unadjusted analysis, patients with low flow had significantly higher rates of mortality (21.9 vs. 7.4%; HR 3.42, 95% CI 1.82-6.43; With respect to health status outcomes, KCCQ scores were available at both baseline and at 30-day follow up in 23 of the low flow 
| D I SCUSSION
In this study, low transaortic flow was associated with increased mortality and HF readmission at 1 year after TAVR. Furthermore, among patients with low flow, the rates of morality and HF were highest among those with preserved LVEF. After adjustment for clinical factors, low flow, but not low AVG or LVEF, was associated with increased 1-year mortality and HF readmission, while low LVEF was associated with a reduction in 1-year mortality. Finally, reduced LVEF, but not low flow or AVG, predicted improved health status outcomes at 30 days.
The findings that low flow predicted increased mortality and HF readmission after TAVR, and that low flow was a stronger predictor than either low AVG or LVEF, are consistent with and build upon the results of prior studies [7, 11, 13, 14] . Most studies that have shown reduced LVEF and AVG to be associated with an increase in mortality and HF after TAVR have not fully adjusted for stroke volume [9, 16] .
However, studies that have adjusted for stroke volume have similarly found that reduced LVEF and AVG are not independently associated with mortality and HF after TAVR [11, 14] . The finding that patients with low flow had a greater need for blood transfusion was unexpected. It is possible that this group had a higher rate of vascular complications, which could account in part for their worse in-hospital outcomes, though this has not been previously seen [11] . Alternatively, it may be that the hemodynamic profile and propensity for heart failure in low flow patients after TAVR predisposed them to longer hospital stays and that the need for blood transfusions was secondary to longer and more complicated hospitalizations.
Conversely, the finding that patients with low flow and preserved LVEF do worse than those with reduced LVEF has not previously been demonstrated [10, 11, 13, 17] . The pathology and hemodynamics associated with low flow and preserved LVEF, including myocardial fibrosis, increased left ventricular afterload, restrictive physiology and reduced left ventricular diastolic filling may be less easily modified by AVR [11, 18, 19] . Still, prior studies have shown either no association between low flow and LV function or improved outcomes among those with preserved LVEF [10, 11, 13, 17] . There are several possible explanations for the findings in this study. TAVR is associated with a higher incidence of paravalvular regurgitation compared with SAVR. Moderate to severe paravalvular regurgitation has been shown to be associated with worse outcomes [20] . Paravalvular regurgitation may be particularly poorly tolerated in patients with low flow and preserved LVEF, and a higher incidence among those patients in this study may be partially responsible for the results.
Another possible explanation for the poor outcomes among patients with low flow and preserved LVEF is undiagnosed amyloidosis.
Prior studies have shown that a significant proportion of patients with heart failure with preserved LVEF have undiagnosed senile amyloidosis [21, 22] . In addition, senile amyloidosis and calcific aortic stenosis share a common demographic, and studies have described their coexistence in patients [23] . Amyloidosis is associated with a restrictive cardiomyopathy, characterized by biventricular wall thickening, loss of ventricular elasticity, and impaired ventricular relaxation [24] . While there are no studies evaluating the outcomes of TAVR in patients with amyloidosis and AS, this hemodynamic profile may be unlikely to benefit from TAVR, and may be particularly poorly suited to tolerate paravalvular regurgitation.
Another possible explanation for the difference in outcomes among low flow patients with preserved and reduced LVEF may be that the patients with reduced LVEF in fact did better than expected.
Low flow may be a marker of more severe and less reversible While the survival benefit for all patients with reduced LVEF was unexpected, the findings that these patients did not suffer increased mortality or HF readmission, and the association with improved health status outcomes, is consistent with some prior studies [9, 11] . These data further support the safety and efficacy of TAVR in patients with reduced LVEF. Likewise, while low flow may be a predictor of poorer outcomes after TAVR, there is ample data to suggest that these patients do indeed still benefit from AVR and that AVR is superior to medical therapy [10, 11, 25] . As such, while flow may be a useful prognostic tool, it should not prohibit the offering of TAVR.
| S T U DY LI M I TA TI ON S
There are several notable limitations to our study. which is known to impact outcomes after AVR, were not available for most patients [26] . Fifth, the majority of patients in this cohort were treated with early generation TAVR devices that were associated with moderate to severe paravalvular regurgitation in upwards of 10% of patients. Patients with low flow, low AVG, and preserved LVEF may be more susceptible to the adverse outcomes associated with paravalvular regurgitation given presumed altered myocardial physiology. Whether these worse outcomes would be seen in a cohort of patients treated with later generation TAVR devices designed to minimize paravalvular regurgitation is not known.
Finally, many of our patients were followed at other institutions and our knowledge of their follow up course came from phone calls; as such, it is possible that some follow up events were not captured.
| F U TU R E RE SEA R CH
There are several potential directions for this work moving forward.
One area that warrants increased attention is the routine method of determining the stroke volume index, which is the product of the LVOT area and flow, divided by the body surface area. The LVOT flow is measured by the velocity-time integral Doppler profile, while the area is determined by measuring the LVOT diameter, usually in the two-dimensional parasternal long axis, and then calculating the area assuming the LVOT is a perfect circle. There are multiple potential measurement errors and incorrect assumptions involved in this process, and in the future, it would be interesting to directly measure the LVOT area by CT scan and see how well this correlated with echocardiographic stroke volume index determination, and how, if at all, the association between flow and outcomes is affected.
Another potential area of future interest is whether the association between flow and outcomes remains in lower risk patients. Interestingly, preliminary data recently presented from a substudy of the PARTNER IIA trial reported no difference in mortality among patients with low flow and low AVG with either preserved or reduced LVEF [27] . This was the first study to assess these parameters and outcomes in a large cohort of intermediate-risk TAVR patients. One possible hypothesis is that the association with low flow and poor outcomes is stronger in higher risk patients due to the presence of confounding conditions, such as frailty or undiagnosed myocardial diseases (i.e., amyloidosis), which may be less prevalent in the lower risk cohort.
Another possible explanation is the increased use of newer generation valves with a lower incidence of paravalvular regurgitation. As such, as the use of TAVR expands into lower risk patients, it will be interesting to see if the association between low flow and poor outcomes remains.
| C ONC LUSI ON
Low transaortic flow is associated with increased mortality and HF after TAVR and is a stronger independent predictor for outcomes than either low AVG or reduced LVEF. In this study, the poor outcomes of patients with low flow were driven by those with preserved LVEF, while patients with low flow and reduced LVEF had similar outcomes to patients with normal flow. Stroke volume index should be part of the routine preoperative evaluation of patients with AS. 
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